Table 3. Disease stage in CRC patients positive for ZNF-specific autoantibodies.
| Dukes stage (n = 95)* | ZNF346 (n = 15) | ZNF638 (n = 10) | ZNF700 (n = 19) | ZNF768 (n = 15) | Cumulative |
|---|---|---|---|---|---|
| A (n = 21) | 19% (4/21) | 0% (0/21) | 28.6% (6/21) | 14.3% (3/21) | 42.9% (9/21) |
| B (n = 31) | 6.5% (2/31) | 9.7% (3/31) | 16.1% (5/31) | 9.7% (3/31) | 32.3% (10/31) |
| C (n = 32) | 21.9% (7/32) | 15.6% (5/32) | 21.9% (7/32) | 18.8% (6/32) | 50% (16/32) |
| D (n = 11) | 18.2% (2/11) | 18.2% (2/11) | 9.1% (1/11) | 27.3% (3/11) | 36.4 (4/11) |
*Dukes stage in one patient not stated.